JP Morgan Chase
ABEO icon

JP Morgan Chase’s Abeona Therapeutics ABEO Stock Holding History

JP Morgan Chase’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-699,000
Closed -$3.68M – 7485
2025
Q4 		$3.68M Buy
+699,000
New +$3.52M ﹤0.01% 3598

Other funds holding ABEO

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

JP Morgan Chase's ABEO Position: Q1 2026 in Review

JP Morgan Chase increased its Abeona Therapeutics (ABEO) stake by 1,148% in Q1 2026, buying an estimated $1.23M and bringing the position to 266,497 shares worth $1.13M. The position accounts for ﹤0.01% of the portfolio, ranked #4526.

JP Morgan Chase first reported a position in ABEO in Q2 2016 and has held it in 35 quarters since. The position peaked at $4.72M in Q2 2025. 108 funds tracked by Wall St. Rank hold ABEO as of Q1 2026.

  • JP Morgan Chase held 266,497 shares of Abeona Therapeutics worth $1.13M as of Q1 2026.
  • JP Morgan Chase bought 245,150 Abeona Therapeutics shares in Q1 2026, an estimated $1.23M.
  • Abeona Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #4526 holding.
  • JP Morgan Chase first reported a position in Abeona Therapeutics in Q2 2016 and has held it in 35 quarters since.
  • JP Morgan Chase's Abeona Therapeutics position peaked at $4.72M in Q2 2025.
  • 108 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.